Xbrane Biopharma AB (publ) (STO:XBRANE)

Sweden · Delayed Price · Currency is SEK

7.44

+0.14 (1.92%)

Apr 10, 2026, 5:29 PM CET

Revenue by Segment

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Biosimilar Development			238.73M	57.62M	10.71M			-	-
Biosimilar Development Growth			314.33%	438.03%	-			-	-
Long-Acting Injectable Drugs			-	-	-			20.49M	20.77M
Long-Acting Injectable Drugs Growth			-	-	-			-1.38%	-
Total			238.73M	57.62M	10.71M			20.49M	20.77M
Total Growth			314.33%	438.03%	-			-1.38%	-

Revenue by Geography

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Germany			209.90M	-	-			-	-
North America			28.70M	-	-			-	-
Middle East			-	-	-			20.49M	20.77M
Middle East Growth			-	-	-			-1.38%	-
Total			238.60M	-	-			20.49M	20.77M
Total Growth			-	-	-			-1.38%	-

Source: S&P Global Market Intelligence.